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received 40 mg dexamethasone over the course of
4 days. By day 20 the patient had recovered.
Conﬂicting results concerning the clinical efﬁc-
acy of pristinamycin against macrolide-resistant
S. pneumoniae with the MLSB phenotype have
been reported [1,9,10]. In a double-blind study
comparing the efﬁcacy of pristinamycin with
amoxycillin for the treatment of community-
acquired pneumonia, pristinamycin was signiﬁ-
cantly less effective than amoxycillin (63.6% vs.
86.6%) in bacteraemic patients, with a 50% failure
rate for macrolide-resistant S. pneumoniae [2].
Taken together, these data emphasise the need
to reconsider the choice of pristinamycin or
quinupristin ⁄dalfopristin for the treatment of
macrolide-resistant pneumococcal infections.
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First community-acquired methicillin-
resistant Staphylococcus aureus (MRSA)
strains in Croatia
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The recent article in CMI by Kluytmans-Vanden-
Bergh and Kluytmans [1] described the current
situation concerning community-acquired methi-
cillin-resistant Staphylococcus aureus (CA-MRSA)
infections. CA-MRSA is becoming an increasing
public health problem worldwide, and it was
concluded that reported prevalence rates of CA-
MRSA probably vary among countries because of
the different deﬁnitions used to distinguish
between CA-MRSA and hospital-acquired MRSA
(HA-MRSA), and because of the different settings
in which the studies have been undertaken. We
would like to report the ﬁrst infections in the
community attributable to MRSA that have been
observed at the University Hospital for Infectious
Diseases in Zagreb, Croatia.
Four S. aureus isolates were recovered from
skin and soft-tissue infections and nasal swabs
from two outpatients and one inpatient hospital-
ised in the Trauma Hospital in Zagreb. These
isolates had a low level of resistance to oxacillin,
penicillin, tetracyclines and kanamycin, and were
susceptible to other anti-staphylococcal antimi-
crobial agents tested. Two pulsed-ﬁeld gel elec-
trophoresis (PFGE) types, designated A and G,
were identiﬁed, and these were identical to the
Polish MRSA clones, HeMRSA-Pol4 (PFGE type
A) and HeMRSA-Pol2 (PFGE type G), described
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previously [2]. Three isolates recovered from the
two outpatients shared PFGE type G1, clonal type
ST80-IV and agr type 3, and harboured Panton–
Valentine leukocidin genes. Only spa typing
showed a slight genetic differentiation, reﬂected
in spa types t044, t376 and t131, but there was a
clear relationship among the isolates. According
to molecular epidemiological deﬁnitions, these
three isolates were classiﬁed as CA-MRSA be-
cause they possessed SCCmec type IV and were
unrelated phylogenetically to HA-MRSA clonal
lineages described previously [3]. The remaining
isolate belonged to the Berlin MRSA clone [3],
with PFGE pattern A12, clonal type ST45-IV, agr
type 1 and spa type t015; the Panton–Valentine
leukocidin genes were not detected. No similar
strain has ever been isolated from the same
hospital, and it was therefore considered that this
isolate originated from the patient’s endogenous
ﬂora. However, the epidemic potential of the
Berlin MRSA clone has been demonstrated in
previous studies, especially in the hospital envi-
ronment [2,3].
CA-MRSA isolates have recently been reported
in hospital environments, where they can cause
nosocomial infections. However, there are also
suggestions that the increase in MRSA in the
community results largely from the introduction
of healthcare-associated strains into the environ-
ment [4]. Therefore, a deﬁnition of CA-MRSA and
HA-MRSA based on exclusively epidemiological
data might be too narrow and thus insufﬁcient.
The above ﬁndings support the overall conclusion
of Kluytmans-VandenBergh and Kluytmans [1]
that additional well-designed community-based
studies are required that use adequate risk-factor
analysis to elucidate the epidemiology of CA-
MRSA and to control the spread of MRSA.
The Croatian CA-MRSA isolates were related
genetically to the Mediterranean and Berlin
MRSA clones described previously [5,6]. This
observation, and those from other countries,
have conﬁrmed that dissemination of a single
CA-MRSA clone has not occurred, but rather that
CA-MRSA strains have arisen from diverse
genetic backgrounds in different locations [5].
Multiple genotypes of CA-MRSA are increasingly
causing community-acquired infections, and this
is particularly the case for the ST80-SCCmec IV
CA-MRSA (the ‘Mediterranean clone’), which has
disseminated among a number of European
countries [5,6].
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Evolving trends in infective endocarditis:
comparison with 156 cases from the
National Survey in Slovakia
10.1111/j.1469-0691.2006.01439.x
The interesting review on infective endocarditis
(IE) in CMI by Hill et al. [1] discussed the
changing trends in risk-factors, aetiology and
mortality during the last 20 years. We reviewed
156 cases of IE between 1995 and 2002 in a single
National Cardiology Institute in Slovakia with 180
beds (Table 1) and found a relatively high pro-
portion of cases (33.3%) with staphylococcal
aetiology, but a low incidence (14.5%) of cases
involving Streptococcus viridans. In contrast to the
observations of Hill et al. [1], no cases of Candida
IE were detected, and the prevalence of neuro-
logical complications was < 10% (compared with
20–40%). Comparing mortality rates, Hill et al. [1]
estimated 20–25% ﬁrst-year mortality, compared
with only 5.8% in our cohort, perhaps because all
156 of our cases were treated with antibiotics plus
cardiosurgical native valve (NV) replacement (17
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